Bose Kochupurakkal

Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids

Sarah J. Hill, Brennan Decker, Emma A. Roberts et al. · Cancer Discovery · 2018 · 457 citations · Full text

Life Sciences, Cancer Biology, Oncology +17

Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer

Anniina Färkkilä, D. Gulhan, Julia Casado et al. · Nature Communications · 2020 · 341 citations · Full text

Medicine, Immunology, Oncology +17

A first-in-class polymerase theta inhibitor selectively targets homologous-recombination-deficient tumors

Jia Zhou, Camille Gelot, Constantia Pantelidou et al. · Nature Cancer · 2021 · 337 citations · Full text

Life Sciences, Molecular Biology, Oncology +11

CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer

Shawn F. Johnson, Cristina Cruz, Ann Katrin Greifenberg et al. · Cell Reports · 2016 · 286 citations · Full text

Medicine, Cancer Biology, Oncology +16

Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial

Panagiotis A. Konstantinopoulos, William T. Barry, Michael J. Birrer et al. · The Lancet Oncology · 2019 · 262 citations

Medicine, Oncology, Pharmacology +13